De-risking the Manufacturing of Cell Therapies through Virus-Inactivated Products, Upcoming Webinar Hosted by Xtalks

Share Article

In this free webinar, the featured speakers will discuss the challenges posed by human blood-derived ancillary materials and the strategies employed by suppliers to mitigate these risks. Attendees will also learn about a layered approach to providing safe and effective therapeutic biologics.

As advanced therapies progress through the clinical pipeline, the integrity of the materials used during manufacture becomes increasingly critical.

As advanced therapy developers approach approval and commercialization, they adopt increasingly robust risk-based approaches to ancillary material qualification. Ancillary material qualification is defined by USP 1043 as “the process of acquiring and evaluating data to establish the source, identity, purity, biological safety, and overall suitability of a specific ancillary materials.”

As advanced therapies progress through the clinical pipeline, the integrity of the materials used during manufacture becomes increasingly critical. This session focuses on the challenges that human blood-derived ancillary materials pose, and on the strategies employed by suppliers to mitigate the potential risks they present.

These include extensive donor-screening practices and testing for infectious transmissible agents, the application of current good manufacturing practices (cGMP) during production, and the implementation of robust safety testing on the finished products. In addition, the implementation of virus inactivation processes offers an additional layer of safety as well as lot-to-lot consistency.

Join Robert Margolin, Vice President of Global Sales, Akron Biotech; Richard McFarland, PhD, President, Standards Coordinating Body for Gene, Cell, and Regenerative Medicines and Cell-Based Drug Discovery (SCB) & Chief Regulatory Officer, Advanced Regenerative Manufacturing Institute (ARMI); and Raymond Luke, Associate Director of Process Sciences (Manufacturing Science & Technology), Adaptimmune in a live webinar on Thursday, March 11, 2021 at 1pm EST.

For more information, or to register for this event, visit De-risking the Manufacturing of Cell Therapies through Virus-Inactivated Products.

ABOUT AKRON BIOTECH

Akron is a leading materials manufacturer and services provider to the regenerative medicine industry. An ISO 13485-certified company operating in line with cGMP guidelines and international standards, Akron leverages more than 100,000 square feet of development and manufacturing capacity to provide advanced therapy developers the scale, compliance, and regulatory support necessary to drive novel treatments from discovery to commercialization. For more information, please visit http://www.akronbiotech.com.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year, thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com
For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Sydney Perelmutter
Xtalks
+1 (416) 977-6555 x 352
Email >
Visit website